TERT-TP53 mutations: a novel biomarker pair for hepatocellular carcinoma recurrence and prognosis
Abstract Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer, and ranks among the most lethal malignancies globally, primarily due to its high rates of recurrence and metastasis. Despite the urgency, no reliable biomarkers currently exist for predicting tumor recurrence in HCC....
Saved in:
Main Authors: | Jin Li, Ling Bai, Zhaodan Xin, Jiajia Song, Hao Chen, Xingbo Song, Juan Zhou |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2025-01-01
|
Series: | Scientific Reports |
Subjects: | |
Online Access: | https://doi.org/10.1038/s41598-025-87545-z |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A Primer on the Role of TP53 Mutation and Targeted Therapy in Endometrial Cancer
by: Bohao Zhang, et al.
Published: (2025-01-01) -
TERT promoter mutations in thyroid cancer
by: Michiko Matsuse, et al.
Published: (2023-11-01) -
Prognostic model and immune-infiltrating cell landscape based on differentially expressed autophagy-related genes in TP53-mutated multiple myeloma
by: Yan-Hua Zheng, et al.
Published: (2021-07-01) -
TP53 germline testing and hereditary cancer: how somatic events and clinical criteria affect variant detection rate
by: Paula Rofes, et al.
Published: (2025-01-01) -
Impact of EML4‐ALK Variants and TP53 Status on the Efficacy of ALK Inhibitors in Patients With Non‐small Cell Lung Cancer
by: Zihua Zou, et al.
Published: (2025-01-01)